UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 ________________________________
 FORM 10-K/A
 (Amendment No. 1)
 (Mark One)

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year ended December 31, 2022
 or

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 Commission File Number 000-30347
 CURIS, INC.
 (Exact Name of Registrant as Specified in Its Charter)

 Delaware
 04-3505116

 (State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification No.)

 128 Spring Street, Building C - Suite 500, Lexington, Massachusetts, 02421
 (Address of principal executive offices) (Zip Code)
 617 - 503-6500
 (Registrant's telephone number, including area code)
 ________________________________
 Securities registered pursuant to Section 12(b) of the Act:

 Title of Each Class
 Trading Symbol(s)
 Name of Each Exchange on Which Registered

 Common Stock, $0.01 par value per share
 CRIS
 Nasdaq Capital Market

 Securities registered pursuant to Section 12(g) of the Act: None
 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No x
 Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No x
 Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes No
 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x Yes No
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large accelerated filer

 Accelerated filer

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal
 control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
 issued its audit report.
 If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
 Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to § 240.10D-1(b).
 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No x
 The aggregate market value of the registrant's common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) based on the last reported sale price of the common stock on June 30, 2022 was approximately $ 89.7 million. As of December 18, 2023, there were 5,894,085 shares of the registrant's common stock outstanding.

 EXPLANATORY NOTE
 This Amendment No. 1 to Form 10-K (this "Amendment") amends the Annual Report on Form 10-K of Curis Inc. ("Curis", "we", "us" or "our") for the year ended December 31, 2022, which was originally filed with the Securities and Exchange Commission (the "SEC") on March 13, 2023 (the "Original Form 10-K"). The sole purpose of this Amendment is to add to Part II, Item 9A, "Controls and Procedures," a statement reflecting the conclusion of our chief executive officer and chief financial officer that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2022. This statement was inadvertently omitted from the Original Form 10-K. The complete text of Part II, Item 9A, as amended and restated, is included in this Amendment.
 In connection with the foregoing, and pursuant to the rules of the SEC, we are including with this Amendment certain new certifications by our principal executive officer and principal financial officer. Accordingly, we are including the complete text of Part IV, Item 15, as amended and restated, in this Amendment, which reflects the filing of Exhibit 31.3 and Exhibit 31.4.
 Other than with respect to the foregoing, this Amendment does not modify or update in any way the disclosures made in the Original Form 10-K. This Amendment does not otherwise update information in the Original Form 10-K to reflect facts or events occurring subsequent to the filing date of the Original Form 10-K. This Amendment should be read in conjunction with the Original Form 10-K and with any of our filings made with the SEC subsequent to filing of the Original Form 10-K.

 ITEM 9A.CONTROLS AND PROCEDURES
 Evaluation of Disclosure Controls & Procedures
 Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
 Management's Report on Internal Control Over Financial Reporting
 Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
 • pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
 • provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of management and our board of directors; and
 • provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.
 Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of evaluations of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. In making this assessment our management used the criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO.
 Based on our assessment, management concluded that, as of December 31, 2022, our internal control over financial reporting is effective based on the criteria established in Internal Control—Integrated Framework (2013) issued by COSO.
 Changes in Internal Control Over Financial Reporting
 There have been no changes in our internal control over financial reporting, as such term is defined in Rules 13(a)-15(f) and 15(d)-15(f) promulgated under the Securities Exchange Act of 1934, during the fourth quarter of 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 ITEM 15.EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
 (a)(1) Financial Statements.

 Page number
of the Original Form 10-K

 Curis, Inc. and Subsidiaries

 Report of Independent Registered Public Accounting Firm ( PricewaterhouseCoopers LLP, Boston, Massachusetts, PCAOB ID 238)

 Consolidated Balance Sheets as of December 31, 2022 and 2021

 Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2022 and 2021

 Consolidated Statements of Stockholders' Equity (Deficit) for the Years Ended December 31, 2022 and 2021

 Consolidated Statements of Cash Flows for the Years Ended December 31, 2022 and 2021

 Notes to Consolidated Financial Statements

 (a)(2) Financial Statement Schedules.
 All schedules are omitted because they are not applicable or the required information is shown in the Financial Statement or Notes thereto.
 (a)(3) List of Exhibits.

 No.

 Form

Date

 Articles of Incorporation and By-laws

 3.1

 Restated Certificate of Incorporation of Curis, Inc., as amended

 Link

 11/9/2021

 3.1

 3.2

 Certificate of Designations of Curis, Inc.

 Link

 S-3 (333-50906)

 8/10/2001

 3.2

 3.3

 Amended and Restated By-laws of Curis, Inc.

 Link

 3.3

 Instruments defining the rights of security holders, including indentures

 4.1

 Form of Curis Common Stock Certificate

 Link

 3/1/2004

 4.1

 4.2

 Description of Registrants' Securities

 Link

 4.2

 Material contracts—Management Contracts and Compensatory Plans

 #10.1

 Employment Agreement, dated March 29, 2016, as amended September 24, 2018 by and between Curis, Inc. and James E. Dentzer.

 Link

 11/1/2018

 10.2

 #10.2

 Employment Agreement, dated August 4, 2022, by and between Curis, Inc. and Diantha Duvall

 Link

 11/9/2022

 10.1

 No.

 Form

Date

 #10.3

 Employment Agreement, dated September 11, 2019, by and between Curis, Inc. and William E. Steinkrauss

 Link

 11/5/2019

 10.1

 #10.4

 Employment Agreement, dated June 1, 2018, by and between Curis, Inc. and Robert E. Martell, M.D., Ph. D.

 Link

 8/2/2018

 10.2

 #10.5

 Consulting Agreement, dated June 29, 2022, by and between Curis, Inc. and William E. Steinkrauss

 Link

 8/4/2022

 10.1

 #10.6

 Form of Indemnification Agreement, by and between Curis, Inc. and each non-employee director of the Board of Directors of Curis, Inc.

 Link

 8/7/2014

 10.3

 #10.7

 Curis 2010 Stock Incentive Plan

 Link

 Def 14A

 4/16/2010

 Exhibit A

 #10.8

 Curis 2010 Employee Stock Purchase Plan

 Link

 Def 14A

 4/16/2010

 Exhibit B

 #10.9

 Form of Incentive Stock Option Agreement for awards granted to named executive officers under Curis' 2010 Stock Incentive Plan

 Link

 6/4/2010

 10.1

 #10.10

 Form of Non-Statutory Stock Option Agreement for awards granted to directors and named executive officers under Curis' 2010 Stock Incentive Plan

 Link

 6/4/2010

 10.2

 #10.11

 Form of Restricted Stock Agreement for awards granted to directors and named executive officers under Curis' 2010 Stock Incentive Plan

 Link

 6/4/2010

 10.3

 #10.12

 Curis Amended and Restated 2010 Stock Incentive Plan, as amended

 Link

 5/28/2015

 99.1

 #10.13

 Form of Incentive Stock Option Agreement for awards granted to named executive officers under Curis' Amended and Restated 2010 Stock Incentive Plan, as amended

 Link

 10.21

 #10.14

 Form of Non-Statutory Stock Option Agreement for awards granted to directors and named executive officers under Curis' Amended and Restated 2010 Stock Incentive Plan, as amended

 Link

 10.22

 #10.15

 Form of Restricted Stock Agreement for awards granted to directors and named executive officers under Curis' Amended and Restated 2010 Stock Incentive Plan, as amended

 Link

 10.23

 #10.16

 Form of Incentive Stock Option Agreement (Online Acceptance) for awards granted to named executive officers under Curis' Amended and Restated 2010 Stock Incentive Plan

 Link

 3/9/2017

 10.21

 #10.17

 Form of Nonstatutory Stock Option Agreement (Online Acceptance) granted to directors and named executive officers under Curis' Amended and Restated 2010 Stock Incentive Plan

 Link

 3/9/2017

 10.22

 #10.18

 Curis Second Amended and Restated 2010 Stock Incentive Plan

 Link

 5/22/2017

 99.1

 No.

 Form

Date

 #10.19

 Form of Incentive Stock Option Agreement for awards granted to named executive officers under Curis' Second Amended and Restated 2010 Stock Incentive Plan

 Link

 10.27

 #10.20

 Form of Non-Statutory Stock Option Agreement for awards granted to directors and named executive officers under Curis' Second Amended and Restated 2010 Stock Incentive Plan

 Link

 10.28

 #10.21

 Form of Restricted Stock Agreement for awards granted to directors and named executive officers under Curis' Second Amended and Restated 2010 Stock Incentive Plan

 Link

 10.29

 #10.22

 Form of Nonstatutory Stock Option Agreement - Inducement Grant pursuant to Nasdaq Stock Market Rule 5635(c)(4)

 Link

 S-8

 1/6/2017

 99.1

 #10.23

 Curis Third Amended and Restated 2010 Stock Incentive Plan, as amended

 Link

 6/10/2020

 99.1

 #10.24

 Form of Incentive Stock Option Agreement for awards granted to named executive officers under Curis' Third Amended and Restated 2010 Stock Incentive Plan

 Link

 2/24/2022

 10.2

 #10.25

 Form of Non-Statutory Stock Option Agreement for awards granted to directors and named executive officers under Curis' Third Amended and Restated 2010 Stock Incentive Plan

 Link

 2/24/2022

 10.2

 #10.26

 Curis Fourth Amended and Restated 2010 Stock Incentive Plan

 Link

 6/2/2021

 99.1

 #10.27

 Curis Amended and Restated 2010 Employee Stock Purchase Plan, as amended

 Link

 10.31

 Material contracts—Leases

 10.28

 Lease, dated December 5, 2019, by and between Curis, Inc. and 128 Spring Street Lexington, LLC relating to the premises at 128 Spring Street, Lexington, Massachusetts

 Link

 12/6/2019

 10.1

 10.29

 First Amendment to Lease Agreement, dated January 27, 2022, by and between Curis, Inc. and 99 Hayden, LLC, successor-in-interest to 128 Spring Street Lexington, LLC

 Link

 2/2/2022

 10.1

 Material contracts—Financing Agreements

 10.30

 Consent and Payment Direction Letter Agreement, dated November 20, 2012 and effective as of December 11, 2012 by and between Curis, Inc., Curis Royalty LLC and Genentech, Inc.

 Link

 3/13/2013

 10.32

 10.31

 Consent and Payment Direction Letter Agreement, dated March 3, 2017 by and between Curis, Inc., Curis Royalty LLC and Genentech, Inc.

 Link

 3/9/2017

 10.28

 10.32

 Purchase and Sale Agreement, dated as of December 11, 2012 between Curis, Inc. and Curis Royalty LLC

 Link

 10.32

 No.

 Form

Date

 10.33

 Royalty Interest Purchase Agreement, dated March 22, 2019, by and between, Curis, Inc., Curis Royalty LLC, a wholly owned subsidiary of Curis, Inc., TPC Investments I LP and TPC Investments II LP

 Link

 3/26/2019

 10.40

 10.34

 Security Agreement, dated March 22, 2019, by and between, Curis Royalty LLC, a wholly owned subsidiary of Curis, Inc., TPC Investments I LP and TPC Investments II LP

 Link

 3/26/2019

 10.41

 10.35

 Pledge Agreement, dated March 22, 2019, by and between, Curis, Inc., TPC Investments I LP and TPC Investments II LP

 Link

 3/26/2019

 10.42

 10.36

 Consent and Payment Direction Letter Agreement, dated March 22, 2019, by and between Curis, Inc., Curis Royalty LLC and Genentech, Inc.

 Link

 3/26/2019

 10.43

 Material contracts—License and Collaboration Agreements

 10.37

 Collaborative Research, Development and License Agreement, dated June 11, 2003, by and between Curis, Inc. and Genentech, Inc.

 Link

 8/6/2015

 10.1

 10.38

 Collaboration, License and Option Agreement, dated January 18, 2015, by and between Curis, Inc. and Aurigene Discovery Technologies Limited

 Link

 2/24/2022

 10.36

 10.39

 First Amendment to Collaboration, License and Option Agreement, dated September 7, 2016, by and between Curis, Inc. and Aurigene Discovery Technologies Limited

 Link

 2/24/2022

 10.37

 10.40

 Second Amendment to Collaboration, License and Option Agreement, dated February 5, 2020, by and between Curis, Inc. and Aurigene Discovery Technologies Limited

 Link

 3/19/2020

 10.41

 10.41

 Option and License Agreement, dated January 6, 2020 by and between Curis, Inc and ImmuNext, Inc.

 Link

 3/19/2020

 10.42

 Material contracts—Miscellaneous

 10.42

 Common Stock Purchase Agreement, dated January 18, 2015, by and between Curis, Inc. and Aurigene Discovery Technologies Limited

 Link

 2/24/2015

 10.34

 10.43

 Stock Purchase Agreement, dated September 7, 2016, by and between Curis, Inc. and Aurigene Discovery Technologies Limited

 Link

 11/3/2016

 10.3

 10.44

 Registration Rights Agreement, dated January 18, 2015, by and between Curis, Inc. and Aurigene Discovery Technologies Limited

 Link

 2/24/2015

 10.35

 10.45

 Registration Rights Agreement, dated September 7, 2016, by and between Curis, Inc. and Aurigene Discovery Technologies Limited

 Link

 11/3/2016

 10.4

 10.46

 Form of Securities Purchase Agreement, dated June 11, 2020, by and among Curis, Inc. and the Purchasers named therein

 Link

 6/11/2020

 10.1

 10.47

 Sales Agreement, dated March 16, 2021, by and among Curis, Inc., Cantor Fitzgerald & Co. and JonesTrading Institutional Services, LLC

 Link

 S-3ASR

 3/16/2021

 1.2

 No.

 Form

Date

 Code of Conduct

 Amended and Restated Code of Business Conduct and Ethics

 Link

 Additional Exhibits

 Subsidiaries of Curis

 Link

 23.1

 Consent of PricewaterhouseCoopers LLP

 Link

 23.1

 31.1

 Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act/15d-14(a) of the Exchange Act

 Link

 31.1

 31.2

 Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act/15d-14(a) of the Exchange Act

 Link

 31.2

 31.3

 Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act/15d-14(a) of the Exchange Act

 Link

 X

 31.4

 Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act/15d-14(a) of the Exchange Act

 Link

 X

 32.1

 Certification of the Chief Executive Officer pursuant to Rule 13a-14(b)/15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350

 Link

 32.1

 32.2

 Certification of the Chief Financial Officer pursuant to Rule 13a-14(b)/15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350

 Link

 32.2

 101.INS

 X

 101.SCH

 X

 101.CAL

 X

 101.DEF

 X

 101.LAB

 X

 101.PRE

 X

 Cover Page Interactive Data File

 X

 # Indicates management contract or compensatory plan or arrangement.

 Confidential treatment has been granted as to certain portions, which portions have been separately filed with the Securities and Exchange Commission.

 Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

 SIGNATURES
 Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 CURIS, INC.

 By:

 /s/ JAMES DENTZER

 James Dentzer
President and Chief Executive Officer

 Date: December 21, 2023